0.047 and 0.117, respectively. Overall, among the ALL patients only 20.6% carried at least one of the polymorphisms, while this rate was 34.6% within the control population. This difference is statistically significant (w 2 ¼ 5.2266, Po0.025). The results are summarized in Table 1 . No significant differences were observed concerning ALL immunophenotype, sex, age at diagnosis, survival rate, or risk of relapse.
reported a lower frequency of A3V and T9I in patients with multiple myeloma as compared to the control population and discussed their potential protective effects. However, in this study, no significant difference was found between ALL patients (n ¼ 70) and controls (n ¼ 220) regarding the frequencies of wild-type and variant LIGIV gene. Since multiple myeloma is not found in childhood and no age was provided for the ALL patients, it is reasonable to assume that this study population consisted of adults. In support of our study on childhood ALL, recent data indicate that T9I might reduce the risk for nonHodgkin's lymphomas as well. 8 The LIGIV isoform carrying the variants A3V and T9I has been shown to display a 2-to 3-fold reduced ligation activity. 5 Considering the essential role of DNA repair for the maintenance of genomic stability and the important functions of NHEJ for the repair of DSB, a protective effect of polymorphisms potentially decreasing the NHEJ activity in a central component of the NHEJ pathway might be surprising. However, there is growing evidence that NHEJ could be error-prone and could in fact create chromosomal translocations frequently seen in leukemic cells. Chromosomal translocations involving the MLL gene are found in about 80% of infant leukemias, and NHEJ could be involved in these recombination events as well. Some features point to a potential involvement of NHEJ in the creation of the chromosomal translocation t(12;21), the most common genetic rearrangement in childhood ALL, 1 resulting in the fusion protein ETV6/RUNX1 (TEL/AML1) (reviewed in Rassool 2 ). Thus, it seems possible that a decrease of NHEJ activity could reduce the formation of potentially threatening frameshift mutations and translocations and, thereby, prevent the development of cancer. Whether or not the polymorphisms A3V and T9I alone and in heterozygous form could influence the LIGIV activity, still remains to be elucidated. The recovery of absolute lymphocyte count (ALC) after CHOP or rituximab plus CHOP (R-CHOP) chemotherapy has been determined as an independent prognostic factor of survival in patients with diffuse large B-cell lymphoma (DLBCL). 1 This finding suggests the importance of ALC recovery (that is, host immunity) in predicting the survival of DLBCL patients after chemotherapy.
1,2 Furthermore, a recent study suggested that the ALC at the time of diagnosis, not at the time of recovery after chemotherapy, would predict the prognosis of 228 patients with follicular lymphoma (FL). 3 FL patients with high ALCs at Abbreviation: ALL, acute lymphoblastic leukemia.
Letters to the Editor diagnosis (X1.0 Â 10 9 /l) showed better overall survival compared to those with lower ALCs, and ALC was an independent prognostic factor in addition to the follicular lymphoma international prognostic index (FLIPI). However, to our best knowledge, the predictive value of the ALC at diagnosis for survival or response to chemotherapy has never been investigated in patients with DLBCL. The objective of the current study was to define the prognostic role of ALCs at diagnosis in predicting the response to chemotherapy and survival after treatment.
A total of 223 patients with CD20-positive DLBCL who received CHOP or R-CHOP chemotherapy between 1997 and 2005 at six hospitals in Republic of Korea (Korean Cancer Center Hospital, Kyungpook National University Hospital, Chonnam National University Hwasun Hospital, Dongsan Medical Center, Pusan National University Hospital, and Yeungnam Medical Center) were included in this retrospective study. This study was approved by the institutional research board at the Kyungpook National University Hospital (Daegu, Korea). Clinical data were analyzed according to information available as of November 2005. Baseline patients' characteristics are summarized in Supplementary Table 1. CHOP chemotherapy was given to 101 patients, and R-CHOP chemotherapy was given to 122 patients. No difference in baseline characteristics between the CHOP vs R-CHOP groups was noted (data not shown). Of the 223 patients, 12 patients received high-dose chemotherapy with autologous stem cell transplantation.
Mean ALC (7s.e.) at the time of diagnosis was 1.7270.05 Â 10 9 /l. ALC at 25, 50 and 75 percentile was 1.13 Â 10 9 , 1.56 Â 10 9 and 2.23 Â 10 9 /l, respectively. Using an ALC cut-off value of 1.0 Â 10 9 /l at diagnosis, patients were divided into higher and lower ALC groups. Forty-two patients (19%) had lower ALCs at diagnosis. Significant differences were noted between the higher and lower ALC groups in terms of stage (P ¼ 0.004), LDH level (Po0.001), extranodal involvement (P ¼ 0.011), performance status (Po0.001) and international prognostic index (IPI; Po0.001). These correlations suggest that ALCs may represent an additional prognostic parameter in patients with DLBCL. However, there was no association of ALCs with the use of rituximab (P ¼ 0.982), or age (P ¼ 0.539).
Out of 215 patients evaluable for response to chemotherapy, the overall response rate (ORR) was 90% (194/215 patients) with a CR of 77% (165/215 patients) and a partial response (PR) rate of 13% (29/215 patients). A higher ORR was observed in the higher ALC group at diagnosis compared to the lower ALC group (94 vs 77%; P ¼ 0.005; Supplementary Table 1 and Supplementary Figure 1) . The difference in ORR was significant in favor of the higher ALC group in patients receiving R-CHOP (ORR 95 vs 78%; P ¼ 0.019), but not in patients receiving CHOP chemotherapy (ORR 90 vs 77%, P ¼ 0.227).
With a median follow-up duration of 376 days (range 12-5,176 days), 67 patients (30%) relapsed or progressed with 42 deaths (19%). The 1-and 2-year overall survival (OS) rates were 8773 and 7374%, while 1-and 2-year event-free survival (EFS) rates were 7373 and 5874%, respectively. A significant benefit in EFS was noted in the R-CHOP group compared with CHOP group (P ¼ 0.027). However, there was no statistically significant difference in OS between the R-CHOP vs CHOP groups (P ¼ 0.144), possibly due to a relatively short follow-up of the R-CHOP group. A survival benefit was noted in the higher ALC group compared to the lower ALC group with regard to both median duration of OS (3000 days vs 695days, Po0.001; Figure 1a ) and EFS (1773 days vs 326days, Po0.001; Letters to the Editor Figure 1b) . The 2 years OS and EFS rates were 8074 and 6475% in the higher ALC group, and 46711 and 327 10% in the lower ALC group, respectively.
In the R-CHOP group, the higher ALC group showed better survival than the lower ALC group in terms of OS (79710% vs 50717% at 2 years, Po0.001; Figure 1c ) and EFS rate (66713% vs 23718% at 2 years, P ¼ 0.001; Supplementary  Figure 2a ). In the CHOP group, a survival difference was noted in favor of the higher ALC group compared to the lower ALC group in terms of OS (7775% vs 5876%, P ¼ 0.001; Figure 1d ) and EFS (42715% vs 34711%, P ¼ 0.001; Supplementary  Figure 2b) .
The results of the multivariate analysis are summarized in Table 1 . To identify predictive factors for response to first line chemotherapy, a logistic regression analysis was conducted for 210 patients with following variables: stage, IPI score, age, performance status, LDH, extranodal involvement, use of rituximab and ALC at diagnosis (X1.0 vs o1.0 Â 10 9 /l). ALC at diagnosis was found to be an independent factor predicting overall response (P ¼ 0.009, Odds ratio 2.717, 95% CI (1.282-5.747)).
For the multivariate survival analyses using Cox's proportional hazard model to define prognostic factors for OS or EFS, the following variables were included into the final model: stage, IPI score, age, performance status, LDH level, extranodal involvement, use of rituximab and ALC at diagnosis (X1.0 vs o1.0 Â 10 9 /l). ALC at diagnosis was an independent prognostic factor for OS and EFS (Table 1 ). The lower ALC group had 31.6% of 2-year EFS, while the higher ALC group had 64.3% (P ¼ 0.004, HR 2.148, 95% CI. (1.273-3.626) ). In addition, lower IPI at diagnosis and use of R-CHOP were found to be good prognostic factors with regard to EFS. The lower ALC group had 55.0% of 2-year OS, while the higher ALC group had 79.7% (P ¼ 0.002, HR 2.863, 95% CI (1.468-5.582)). Lower IPI at diagnosis was found to be another good prognostic factor for OS, but the use of R-CHOP did not affect OS (Table 1) . Despite correlation between ALC and other prognostic factors, multivariate analyses demonstrated that ALC is an independent prognostic factor for EFS and OS, suggesting the role of ALCs as another prognostic factor in patients with DLBCL.
The current study suggests that host immunocompetence may affect the response to chemotherapy and survival of patients with DLBCL after CHOP/R-CHOP therapy. Several prognostic factors have been reported for DLBCL, among which the IPI has been accepted as a single powerful prognostic factor for predicting the survival of patients with DLBCL. 4 In addition, recent advances in immunotherapy emphasize the importance of host immunocompetence against the tumor. ALC recovery or ALC at diagnosis have been reported to be a surrogate marker of host immunocompetence. A cut-off value of 1.0 Â 10 9 /l was chosen based on a previous study in FL patients. 3 Out of 223 patients, 42 patients (19%) were stratified into the lower ALC group. Based on the present result, the predictive power of ALC at diagnosis on EFS or OS was statistically significant irrespective of frontline chemotherapy regimen, including CHOP or R-CHOP therapy. However, the recovery of ALC after chemotherapy should be also considered as a predictor for successful treatment outcomes. A limitation of the current study includes a relatively short follow-up time, especially in the R-CHOP group.
Another modifiable factor influencing patients' prognosis is the use of a rituximab-containing regimen. Coiffier et al. 5 reported that the group receiving R-CHOP instead of CHOP regimen had a survival benefit. The current study showed that the role of ALCs in predicting response to R-CHOP was more robust than response to CHOP chemotherapy, although the prognostic value of ALC was reproducible in both the R-CHOP and CHOP groups. One of the proposed mechanisms is antibody-dependent cellular cytotoxicity (ADCC) in addition to bcl-2-mediated chemoresistance. 6, 7 Increasing evidence supports the role of natural killer (NK) cells as important mediators of ADCC after binding of rituximab to CD20-positive lymphoma cells. Manches et al. 6 reported that rituximab can induce phagocytosis of lymphoma cells by tissue-scavengering cells such as macrophages or NK cells, important mediators of ADCC. Accordingly, host immunocompetence, reflected by ALC at diagnosis, would predict the response to chemotherapy (especially R-CHOP) and prognosis of patients with DLBCL. Further study to determine lymphocyte subsets responsible for the superior response and outcomes will provide us better understanding of this issue. 
